Antigens, CD20

• 

  Subject Areas on Research

  • A 9-yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-type ADA deficiency. 
  • A frequent human CD20 (B1) differentiation antigen DNA polymorphism detected with MspI is located near 11q12-13. 
  • Analysis of the expression of CD5 by human B cells and correlation with functional activity. 
  • Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report. 
  • Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. 
  • Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. 
  • Antigen retrieval, blocking, detection and visualisation systems in immunohistochemistry: a review and practical evaluation of tyramide and rolling circle amplification systems. 
  • Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. 
  • B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. 
  • B cell depletion reduces the development of atherosclerosis in mice. 
  • B cell-ablative therapy for the treatment of autoimmune diseases. 
  • B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. 
  • B lymphocytes contribute to autoimmune disease pathogenesis: current trends and clinical implications. 
  • B lymphocytes differentially influence acute and chronic allograft rejection in mice. 
  • B-lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice. 
  • B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. 
  • Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. 
  • Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. 
  • CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. 
  • CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. 
  • CD19: a promising B cell target for rheumatoid arthritis. 
  • CD20 deficiency in humans results in impaired T cell-independent antibody responses. 
  • CD20-positive infiltrates in renal allograft biopsies with acute cellular rejection are not associated with worse graft survival. 
  • CD20: a regulator of cell-cycle progression of B lymphocytes. 
  • CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. 
  • Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases. 
  • Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation. 
  • Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19. 
  • Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. 
  • Composite lymphoma of follicular B-cell and peripheral T-cell types with distinct zone distribution in a 75-year-old male patient: a case study. 
  • Determinants of disease in the simian immunodeficiency virus-infected rhesus macaque: characterizing animals with low antibody responses and rapid progression. 
  • Diagnosis and management of pemphigus: Recommendations of an international panel of experts. 
  • Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host. 
  • Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. 
  • Elevated serum L-selectin levels and abnormal regulation of L-selectin expression on leukocytes in atopic dermatitis: soluble L-selectin levels indicate disease severity. 
  • Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. 
  • Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. 
  • Fine-needle aspiration findings in idiopathic retroperitoneal fibrosis. 
  • Follicular lymphoma with hyaline-vascular Castleman disease-like follicles and CD20 positive follicular dendritic cells. 
  • Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms. 
  • Good and bad memories following rituximab therapy. 
  • Heterogeneity in the B1 (CD20) cell surface molecule expressed by human B-lymphocytes. 
  • Human anti-pneumococcal polysaccharide antibodies are secreted by the CD5- B cell lineage. 
  • Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse. 
  • Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells. 
  • Improved antigen binding by a CD20-specific single-chain antibody fragment with a mutation in CDRH1. 
  • Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. 
  • Inhibition of adaptive immune responses leads to a fatal clinical outcome in SIV-infected pigtailed macaques but not vervet African green monkeys. 
  • Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. 
  • Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. 
  • Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain. 
  • Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. 
  • Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. 
  • Mouse CD20 expression and function. 
  • Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. 
  • Prevention trumps treatment of antibody-mediated transplant rejection. 
  • Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice. 
  • Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. 
  • Regulatory B cell (B10 Cell) expansion during Listeria infection governs innate and cellular immune responses in mice. 
  • Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. 
  • Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. 
  • Rituximab in lymphocyte predominance Hodgkin's disease: a case series. 
  • Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus. 
  • Structural organization of the human MS4A gene cluster on Chromosome 11q12. 
  • Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). 
  • Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). 
  • Suppression of adaptive immune responses during primary SIV infection of sabaeus African green monkeys delays partial containment of viremia but does not induce disease. 
  • Systemic and cell type-specific gene expression patterns in scleroderma skin. 
  • The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma. 
  • The gene that encodes the human CD20 (B1) differentiation antigen is located on chromosome 11 near the t(11;14)(q13;q32) translocation site. 
  • The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. 
  • The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. 
  • The significance of single nucleotide polymorphism rs2070770 in CD20 gene in Chinese patients with diffuse large B-cell lymphoma. 
  • Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. 
  • Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. 
  • Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway.